SVA - Sinovac Biotech, Ltd.

Sinovac Biotech Ltd. (SVA) is a China-based biopharmaceutical company that specializes in the research, development, production, and commercialization of vaccines for infectious diseases. The company has a diverse pipeline of vaccines for diseases such as COVID-19, hepatitis A and B, influenza, and human papillomavirus.

Sinovac Biotech's core products include Healive (hepatitis A vaccine), Bilive (combined hepatitis A and B vaccine), Anflu (influenza vaccine), and Panflu (pandemic influenza vaccine). The company's vaccines are marketed in China and sold to international customers in Southeast Asia, South America, and the Middle East.

In response to the COVID-19 pandemic, Sinovac Biotech developed CoronaVac, an inactivated vaccine for the virus. The company conducted clinical trials in several countries, including China, Brazil, Turkey, and Indonesia, and the vaccine was authorized for emergency use in those countries. Sinovac Biotech has also applied for emergency use authorization in several other countries, including the Philippines, Malaysia, and Thailand.

Sinovac Biotech was founded in 2001 and is headquartered in Beijing, China. The company has a global workforce of over 1,000 employees and operates research and development facilities in China, Canada, and the Netherlands. Sinovac Biotech is publicly traded on the NASDAQ stock exchange under the symbol SVA.